New Hospice Bill Proposes Separate Medicare Payments for Blood Transfusions Starting in 2027

When someone enters hospice, the goal is comfort. Currently, Medicare pays hospice providers a flat daily rate—a 'per diem'—that is supposed to cover every single thing the patient needs. But here is the catch: blood transfusions are expensive. Because that one daily payment often doesn't cover the high cost of blood products and the labor to administer them, some hospice programs are forced to decline patients who need regular transfusions to stay alert and comfortable. The 'Improving Access to Transfusion Care for Hospice Patients Act of 2026' aims to fix this financial bottleneck by changing how the math works for end-of-life care.

Unbundling the Care Package

The bill requires the Center for Medicare and Medicaid Innovation (CMI) to test a new model where blood transfusions are paid for separately from the standard hospice daily rate. Under Section 2, Medicare would pay for these transfusions at the same standard rates used for non-hospice patients. For a family caring for a loved one with a condition like leukemia, this could be the difference between staying in a comfortable home-hospice setting or having to choose between hospice care and the transfusions that keep their loved one feeling human. The bill gives CMI exactly one year from the date it is signed to get this program off the ground.

Data-Driven Dignity

This isn't just a blank check; it is a controlled experiment with strict homework. CMI is required to track very specific metrics to see if this change actually helps people. They will be looking at whether patients receiving these transfusions spend fewer days in the ICU or emergency room during their final month of life. For example, if a patient can get a transfusion at their hospice facility instead of being rushed to the ER for severe anemia, it saves the system money and saves the family a stressful, late-night hospital trip. The bill also mandates a look at how many days a person is able to stay in hospice before passing, aiming to see if better access to blood products prevents people from 'dropping out' of hospice to seek treatment elsewhere.

The Long-Term Outlook

By pulling transfusion costs out of the 'all-inclusive' bundle, the legislation addresses a practical barrier that has long frustrated both doctors and families. The evaluation will compare patients in this new model against those in the traditional system, looking at everything from chemotherapy usage in the final 14 days of life to the total frequency of transfusions. While the bill gives CMI broad authority to track 'other areas' they deem appropriate, the primary focus remains clear: seeing if paying for blood separately allows more people to access hospice without sacrificing the treatments that manage their symptoms. For the 25-to-45-year-olds currently navigating care for aging parents, this could mean one less financial barrier to ensuring a loved one's final days are spent in comfort rather than in a hospital waiting room.